Schouten H C, van Putten W L, Hagemeijer A, Blijham G H, Sonneveld P, Willemze R, Slater R, van de Lely J, Verdonck L F, Löwenberg B
University Hospital of Maastricht, The Netherlands.
Bone Marrow Transplant. 1991 Nov;8(5):377-81.
In a prospective study designed to assess the efficacy of autologous bone marrow transplantation (BMT) and allogeneic BMT in patients with acute myeloid leukemia, we analysed the prognostic significance of chromosomal findings for obtaining complete remission (CR), disease-free survival and survival. Patients with a normal karyotype were more likely to achieve CR than patients with an abnormal chromosomal analysis (p = 0.02). There was no difference observed in survival from CR between patients with or without chromosomal abnormalities, nor was there a difference if the analysis was restricted to subgroups of allogeneic or autologous BMT treated patients. Applying prognostic cytogenetic criteria as defined by Keating et al. (remission induction: good risk: t(8;21) or inv(16), intermediate risk: normal or 45,X,-Y or t(15;17) and poor risk: all other; remission duration: good risk: t(15;17) or inv(16), intermediate risk: normal, 45,X,-Y or t(8;21) and poor risk: all other) no differences were observed between good and intermediate prognosis groups, although the poor prognosis group had a reduced CR rate.
在一项旨在评估自体骨髓移植（BMT）和异基因BMT对急性髓细胞白血病患者疗效的前瞻性研究中，我们分析了染色体检查结果对于获得完全缓解（CR）、无病生存期和总生存期的预后意义。核型正常的患者比染色体分析异常的患者更有可能实现CR（p = 0.02）。有或无染色体异常的患者从CR开始的生存期没有差异，在接受异基因或自体BMT治疗的患者亚组中进行分析时也没有差异。应用Keating等人定义的预后细胞遗传学标准（缓解诱导：低危：t(8;21)或inv(16)，中危：正常或45,X,-Y或t(15;17)，高危：所有其他；缓解持续时间：低危：t(15;17)或inv(16)，中危：正常、45,X,-Y或t(8;21)，高危：所有其他），低危和中危预后组之间未观察到差异，尽管高危预后组的CR率较低。
